Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010;28:5327–47.

Article  PubMed  Google Scholar 

Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.

Article  CAS  PubMed  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.

Article  CAS  PubMed  Google Scholar 

Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica. 2020;105:2730–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mikhaeel S, Atallah E. SOHO state of the art updates and next questions | update on treatment-free remission in chronic myeloid leukemia (CML). Clin Lymphoma Myeloma Leuk. 2023;23:333–9.

Article  CAS  PubMed  Google Scholar 

Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–47.

Article  PubMed  PubMed Central  Google Scholar 

Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep. 2021;16:491–9.

Article  PubMed  Google Scholar 

Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27:1511–9.

Article  CAS  PubMed  Google Scholar 

Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30:2317–28.

Article  CAS  PubMed  Google Scholar 

Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–3.

Article  PubMed  Google Scholar 

Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, et al. Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma. 2016;57:341–7.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang M-J, Pinilla-Ibarz J, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia. JAMA Oncol. 2021;7:42–50.

Article  PubMed  Google Scholar 

Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114:160–4.

Article  PubMed  Google Scholar 

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, et al. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018;18:359.

Article  PubMed  PubMed Central  Google Scholar 

Efficace F, Baccarani M. Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most? J Natl Cancer Inst. 2022;114:9–11.

Article  PubMed  Google Scholar 

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.

Article  CAS  PubMed  Google Scholar 

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024: 42:1875–80 Jco2301647.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

Article  CAS  PubMed  Google Scholar 

Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13:63–74.

Article  CAS  Google Scholar 

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554–60.

Article  CAS  PubMed  Google Scholar 

Hinz A, Singer S, Brahler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014;53:958–65.

Article  PubMed  Google Scholar 

Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29:89–96.

Article  PubMed  Google Scholar 

Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–74.

Article  CAS  PubMed  Google Scholar 

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

Article  CAS  PubMed  Google Scholar 

Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res. 2015;24:5–18.

Article  PubMed  Google Scholar 

Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403:248.

Schafer JL, Yucel RM. Computational strategies for multivariate linear mixed-effects models with missing values. J Computational Graph Stat. 2002;11:437–57. 2002/06/01

Article  Google Scholar 

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56.

Article  CAS  PubMed  Google Scholar 

Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, et al. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? : GIMEMA and EORTC Quality of Life Group. Ann Hematol. 2012;91:1371–81.

Article  PubMed  Google Scholar 

Hyland KA, Eisel SL, Hoogland AI, Root JC, Bowles K, James B, et al. Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison. Leuk Lymphoma. 2023;64:415–23.

Article  CAS  PubMed  Google Scholar 

Schoenbeck KL, Tummala S, Goyal NG, Smith CC, Shah NP. Cognitive dysfunction associated with tyrosine kinase inhibitors in patients with CMl in chronic phase. Blood. 2020;136:2–3. 2020/11/05/